We recently published a list of Top 10 Penny Stocks That Will Skyrocket. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other best stocks to penny stocks that will skyrocket.
Is It a Good Time to Diversify Your Portfolio With Small Caps?
On March 21, Jason D. Pride, Chief of Investment Strategy & Research at Glenmede, and Stephen DeNichilo Senior Portfolio Manager at Federated Hermes appeared on a CNBC interview to talk about the favorable sectors in the market. Jason noted that the market needs to calm down on the Magnificent Seven, as this category has been one of the most concentrated sectors in history. He believes that this above-par level of concentration will lead the Magnificent Seven down, similar to what the market saw back in 1999 and the 20s.
This high level of concentration tells a lot about the future performance and as far as the Magnificent Seven stocks are concerned, Jason does not see the future performance coming from this sector. He argues that the future performance will come from sectors that are not too concentrated at the moment such as the small-cap and pretty much the other 493 stocks in the S&P 500. Investors should be looking at diversifying their portfolios as this is the environment where investors should own the risk and the small caps to get better gains moving forward.
In addition, Stephen further added to the discussion by mentioning that to understand the stock market today investors need to look at this basic idea that a stock only moves higher if there are people who want to buy it from you at a better price. Therefore, if everyone already owns the same stocks then there is no one left to buy it at a better price. Stephen noted that the market is currently in an extremely volatile situation where nobody knows the rules of the market. This is due to the series of headlines related to tariffs, inflation, and interest rates. This situation makes it tough for already expensive companies to predict an encouraging outlook. On the other hand, if we look at the small-cap companies and other less concentrated sectors of the market, these stocks are highly undervalued as compared to their history. Stephen says that fast forwarding to 6 to 12 months from today the market will be in a lower interest rate and more confident environment, which is the best-case scenario for small caps to rally.
Our Methodology
To compile the list of the top 10 penny stocks that will skyrocket we used the Finviz stock screener and CNN as our sources. Using the screener we aggregated a list of penny stocks (trading between $1 and $5) with more than 50% analyst upside potential. After sorting the list by market capitalization we cross-checked the upside potential for each stock using CNN and selected companies with more than 100% upside. Lastly, we ranked the stocks based on the number of hedge fund holders as of Q4 2024, sourced from Insider Monkey’s database. Please note that the data was recorded on March 21, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A medical staff in white coats monitoring the progress of cancer immunotherapy trials.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Price: $3.54
Analyst Upside Potential: 464.97%
Number of Hedge Fund Holders: 44
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a biopharmaceutical company focused on developing and delivering tumor-infiltrating lymphocyte (TIL) therapies for the treatment of solid tumor cancers. Its Amtagvi is the first FDA-approved TIL therapy for advanced melanoma. It is an autologous T-cell immunotherapy used for patients with unresectable or metastatic melanoma who have been previously treated with specific therapies such as PD-1 inhibitors.
On March 1, Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on the stock with a price target of $32. The analyst noted that Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) exceeded revenue expectations for Q4 and the full year of 2024, driven by robust demand for its products, Amtagvi and Proleukin. The company also maintained its revenue guidance of $450 million to $475 million for 2025, reflecting confidence in sustained growth. Moreover, progress in tumor-infiltrating lymphocyte therapies, particularly in addressing unmet medical needs like endometrial cancer, was highlighted. Upcoming data releases and advancements in next-generation TIL therapies further support the company’s potential. It is the top penny stock that will skyrocket.
Overall, IOVA ranks 1st on our list of penny stocks that will skyrocket. While we acknowledge the potential of IOVA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IOVA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.
